BR112014032938A2 - uso de peptídeos de glp-1 de longa ação - Google Patents

uso de peptídeos de glp-1 de longa ação

Info

Publication number
BR112014032938A2
BR112014032938A2 BR112014032938A BR112014032938A BR112014032938A2 BR 112014032938 A2 BR112014032938 A2 BR 112014032938A2 BR 112014032938 A BR112014032938 A BR 112014032938A BR 112014032938 A BR112014032938 A BR 112014032938A BR 112014032938 A2 BR112014032938 A2 BR 112014032938A2
Authority
BR
Brazil
Prior art keywords
peptides
long
acting glp
glp
acting
Prior art date
Application number
BR112014032938A
Other languages
English (en)
Inventor
Bjørn Jensen Christine
Frederik Rasmussen Mads
Zdravkovic Milan
Kristensen Peter
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49881374&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014032938(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112014032938A2 publication Critical patent/BR112014032938A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "uso de peptídeos de glp-1 de longa ação". a presente invenção refere-se ao uso de peptídeos de glp-1 de longa ação em certos regimes de dosagem para o tratamento de diabetes tipo 2, obesidade, etc. 23410943v1 1/1 23410943v1
BR112014032938A 2012-07-01 2013-06-21 uso de peptídeos de glp-1 de longa ação BR112014032938A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01
PCT/EP2013/063004 WO2014005858A1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Publications (1)

Publication Number Publication Date
BR112014032938A2 true BR112014032938A2 (pt) 2017-08-01

Family

ID=49881374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032938A BR112014032938A2 (pt) 2012-07-01 2013-06-21 uso de peptídeos de glp-1 de longa ação

Country Status (11)

Country Link
US (2) US9764003B2 (pt)
EP (3) EP4406593A2 (pt)
JP (1) JP6059802B2 (pt)
AU (3) AU2013286177B2 (pt)
BR (1) BR112014032938A2 (pt)
CA (1) CA2877056A1 (pt)
MX (2) MX366405B (pt)
RS (1) RS60432B1 (pt)
RU (1) RU2657573C2 (pt)
SI (1) SI2866825T1 (pt)
WO (1) WO2014005858A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
WO2012140117A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2013139694A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
CA2877056A1 (en) 2012-07-01 2014-01-09 Novo Nordisk A/S Use of long-acting glp-1 peptides
KR102127624B1 (ko) * 2014-10-16 2020-06-29 얀마 파워 테크놀로지 가부시키가이샤 작업 차량
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
BR112020006246A2 (pt) * 2017-10-12 2021-03-30 Novo Nordisk A/S Método para controle do peso de um sujeito em necessidade
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020028907A1 (en) * 2018-08-03 2020-02-06 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
CN114728042A (zh) * 2019-11-06 2022-07-08 诺和诺德股份有限公司 用于痴呆的glp-1受体激动剂
BR112022013795A2 (pt) * 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
EP4359074A2 (en) * 2021-06-24 2024-05-01 Gila Therapeutics, Inc. Methods and kits for inducing satiety and treating metabolic disorders
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN114621339B (zh) * 2021-12-28 2022-09-23 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
WO2023225370A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
ATE382057T1 (de) 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
US20070203058A1 (en) 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
HUE038395T2 (hu) 2003-11-20 2018-10-29 Novo Nordisk As Propilén-glikol tartalmú peptidkészítmények, amelyek elõállításra és injekciós eszközökben történõ alkalmazásra optimálisak
AU2005303777B2 (en) 2004-11-12 2010-12-16 Novo Nordisk A/S Stable formulations of insulinotropic peptides
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP5415938B2 (ja) 2006-04-14 2014-02-12 マンカインド コーポレイション グルカゴン様ペプチド１（ｇｌｐ−１）医薬製剤
EP2121897A4 (en) 2007-03-20 2010-03-31 Nippon Kayaku Kk METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
US8895694B2 (en) 2007-09-05 2014-11-25 Novo Nordisk A/S Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
AU2010212823B2 (en) * 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
CN102791731B (zh) 2009-12-16 2016-04-20 诺沃—诺迪斯克有限公司 Glp-1类似物和衍生物
WO2011138421A1 (en) * 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
CN103906528A (zh) * 2011-06-24 2014-07-02 安米林药品有限责任公司 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
CA2877056A1 (en) 2012-07-01 2014-01-09 Novo Nordisk A/S Use of long-acting glp-1 peptides

Also Published As

Publication number Publication date
JP2015522573A (ja) 2015-08-06
AU2018202504A1 (en) 2018-05-10
US20180085435A1 (en) 2018-03-29
US10335462B2 (en) 2019-07-02
RS60432B1 (sr) 2020-07-31
AU2020202573B2 (en) 2023-04-20
US20150190474A1 (en) 2015-07-09
MX2014014946A (es) 2015-04-08
SI2866825T1 (sl) 2020-07-31
MX2020010693A (es) 2020-11-06
EP3689365A1 (en) 2020-08-05
AU2018202504B2 (en) 2020-05-07
AU2020202573A1 (en) 2020-05-07
EP2866825B1 (en) 2020-04-08
RU2015101826A (ru) 2016-08-20
EP4406593A2 (en) 2024-07-31
JP6059802B2 (ja) 2017-01-11
AU2013286177B2 (en) 2018-04-26
EP2866825A1 (en) 2015-05-06
AU2013286177A1 (en) 2015-01-15
WO2014005858A1 (en) 2014-01-09
RU2657573C2 (ru) 2018-06-14
US9764003B2 (en) 2017-09-19
CA2877056A1 (en) 2014-01-09
MX366405B (es) 2019-07-08

Similar Documents

Publication Publication Date Title
BR112014032938A2 (pt) uso de peptídeos de glp-1 de longa ação
BR112015026325A2 (pt) dosagem oral de compostos glp-1
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
CL2013003454A1 (es) Composicion farmacéutica para prevenir o tratar diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada.
MX371187B (es) Péptidos terapéuticos.
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
MX2014002159A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
CL2015001699A1 (es) Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
CL2013000716A1 (es) Un profarmaco o una sal del mismo que comprende un conjugado de exendina-conector; procedimiento de preparacion de dicho profarmaco; compuestos intermediarios; composicion farmaceutica que lo comprende, util para mejorar el control glucemico en pacientes con diabetes de tipo 2.
EA201590058A1 (ru) Аналоги глюкагона
CL2015003199A1 (es) Peptidos terapeuticos
BR112012017150A2 (pt) formulação de anticorpo e regimes terapêuticos.
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
CL2014001254A1 (es) Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
MX347703B (es) Co-agonistas del receptor de glucagon/glp-1.
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
MX2009011473A (es) Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
UA118558C2 (uk) Пептидна сполука
EA201391764A1 (ru) Агонисты рецептора glp-1/глюкагона длительного действия
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
TR201100150A2 (tr) Suda çözünür dozaj formları
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]